Phaseline

Companies › Nouscom SRL

Nouscom SRL: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GAd20-209-FSP
Genetic vaccine encoding frameshift peptides (FSP) from mismatch repair-deficient tumors
–Phase 1Solid Tumor, Adult–
MVA-209-FSP
Genetic vaccine encoding frameshift peptides (FSP) from mismatch repair-deficient tumors
–Phase 1Solid Tumor, Adult–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04041310GAd20-209-FSPPhase 1Solid Tumor, AdultOncologyOct 2026
NCT04041310MVA-209-FSPPhase 1Solid Tumor, AdultOncologyOct 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.